Hepatocellular carcinoma in a 12‐year‐old child with PiZZ α1‐antitrypsin deficiency
Nedim Hadzic, Alberto Quaglia, Giorgina Mieli‐Vergani – 22 December 2005
Is banding ligation for primary prevention of variceal bleeding as effective as beta‐blockers, and is it safe?
Christos Triantos, Jiannis Vlachogiannakos, Spilios Manolakopoulos, Andrew Burroughs, Alec Avgerinos – 22 December 2005
Parenteral nutrition–associated liver disease and the role for isolated intestine and intestine/liver transplantation
Alan L. Buchman, Kishore Iyer, Jonathan Fryer – 22 December 2005 – Parenteral nutrition–associated liver disease (PNALD) is the most devastating complication of long‐term parenteral nutrition therapy. Because its progression is typically insidious and its long‐term consequences are generally underappreciated, PNALD is often recognized too late, when liver injury is irreversible.
Reply
Stephan Günther, Meike Hass – 22 December 2005
Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd‐Chiari syndrome
Manuel Hernández‐Guerra, Eric López, Pablo Bellot, Carlos Piera, Juan Turnes, Juan G. Abraldes, Jaime Bosch, Juan C. García‐Pagán – 22 December 2005 – Budd‐Chiari syndrome (BCS) causes postsinusoidal portal hypertension, which leads to complications similar to those observed in cirrhosis. However, no studies have investigated whether patients with BCS develop the hyperdynamic circulatory syndrome present in patients with cirrhosis who have portal hypertension.
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C
Yoshiaki Iwasaki, Hiroshi Ikeda, Yasuyuki Araki, Toshiya Osawa, Keiji Kita, Masaharu Ando, Toshinari Shimoe, Kouichi Takaguchi, Noriaki Hashimoto, Toshitsugu Kobatake, Minoru Tomita, Mitsuhiko Kawaguchi, Haruhiko Kobashi, Kohsaku Sakaguchi, Yasushi Shiratori – 22 December 2005 – In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events.
Sickness behaviors in chronic cholestasis: An immune‐mediated process?
Alexander I. Aspinall, David H. Adams – 22 December 2005
Who reads the paper?
Andres T. Blei – 22 December 2005
What is really ongoing during occult HBV reactivation?
Isabelle Chemin, Sophie Alain, Séverine Margeridon, Saad Mrani, Alan Kay, Christian Trépo – 22 December 2005
Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C
Eva Martínez‐Bauer, Javier Crespo, Manuel Romero‐Gómez, Ricardo Moreno‐Otero, Ricard Solá, Nancy Tesei, Fernando Pons, Xavier Forns, José M. Sánchez‐Tapias – 22 December 2005 – Early prediction of response to therapy in genotype 1 chronic hepatitis C is difficult. Two predictive models, a pretreatment scoring model (PreT‐SM) and a fourth week of therapy scoring model (4w‐SM) were constructed in a cohort of 104 patients from a single center (estimation cohort) and validated in a cohort of 141 patients from four independent centers (validation cohort).